C
ongenital heart defects are the single most common type of birth defect and a leading cause of infant death in the United States. 1 Single ventricle (SV) heart disease is the most common form of severe congenital heart defects 2 and comprises a spectrum of congenital cardiac malformations defined by severe underdevelopment of 1 ventricle. SV heart disease is universally fatal without intervention, and although outcomes are improving, >30% of SV heart disease patients die or require transplant within the first year of life, and 10-year survival in this population is only 39% to 50%. 2, 3 Although the SV heart disease can be a morphological right ventricle (RV), left ventricle, or of indeterminate morphology, single RV lesions such as hypoplastic left heart syndrome may be inherently at risk for heart failure (HF) presumably because of inherent limitations in the RV's ability to tolerate increased afterload. [3] [4] [5] [6] As such, eventual HF is a leading cause of death and indication for heart transplant in the SV heart disease population. 3 Although surgical techniques and perioperative care for SV heart disease continue to improve, long-term survival and quality of life ultimately depend on preservation of RV function.
However, the molecular mechanisms underlying failure of the single RV are poorly understood, limiting the ability to identify effective therapies. Moreover, the ability to investigate mechanisms involved in SV HF or effects of pharmacological interventions are limited by the lack of a postnatal animal model of SV heart disease and the difficulties associated with performing in vivo research in children.
Pharmacological treatment of HF in the pediatric population is extrapolated from the adult HF experience, and treatment guidelines are based primarily on expert consensus. 7 In recent clinical trials, the SV heart disease population demonstrated a detrimental trend in response to carvedilol 8 and a lack of benefit in preventing HF with enalapril, 9 medications commonly used to treat adult HF. Given the divergent response to these adult HF medications in the pediatric SV heart disease population, age-related mechanisms governing HF, as well as fundamental differences in RV versus left ventricle failure, likely exist.
Although there are currently no proven medical therapies for the treatment or prevention of HF in the SV heart disease population, selective and competitive phosphodiesterase type-5 inhibitors (PDE5i), such as sildenafil, are increasingly used in children and adults with SV heart disease. However, although sildenafil has been associated with improved hemodynamics, exercise tolerance, and myocardial function by echocardiography in small series of SV heart disease patients, its direct effects outside of the pulmonary vasculature remain largely unknown. [10] [11] [12] [13] PDE5 expression is prominent throughout the pulmonary vasculature and in the coronary vessels, but there is virtually no detectable PDE5 expression in the normal adult myocardium. 14 Thus, the rationale for the use of PDE5i in the SV heart disease population is PDE5 inhibition in the pulmonary vasculature, thereby promoting vascular smooth muscle relaxation, augmenting pulmonary blood flow, and secondarily SV heart disease cardiac output. 15 Correspondingly, PDE5i have been shown to lack any significant direct effects on the myocardium of normal, nonfailing human and animal hearts in vitro. 16, 17 However, recent data in both human HF patients and in animal models of HF suggest that myocardial and cardiomyocytespecific PDE5 expression is increased under conditions of cardiac stress and is physiologically significant. [18] [19] [20] Increased myocardial PDE5, for example, has been shown to be associated with maladaptive myocardial responses, and its inhibition both globally and in cardiomyocytes specifically can have direct beneficial myocardial effects. 21, 22 In the present study, we sought to determine myocardial PDE5 expression and activity in SV heart disease patients relative to nonfailing controls and to evaluate PDE5 localization within the myocardium. In addition, we used a novel model of cardiomyocyte remodeling,
WHAT IS NEW?
• Phosphodiesterase-5 expression and activity are increased in the right ventricular tissue of children with single ventricle (SV) heart disease compared with that in right ventricles of normal children.
• Treatment of rat heart muscle cells (cardiomyocytes) with sera from children with SV heart disease results in similar pathological gene expression changes as are seen in SV heart tissue.
• Phosphodiesterase-5 inhibitor treatment results in normalization of some of the transcriptional changes seen in the SV heart disease serumtreated cardiomyocytes.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Remodeling (pathological hypertrophy and cardiac dysfunction) of the SV heart can lead to heart failure and death or the need for heart transplant.
• There are no proven therapies and a limited understanding of the mechanisms underlying SV heart failure.
• Elevation of phosphodiesterase-5 in heart tissue may contribute to SV heart failure.
• Phosphodiesterase-5 inhibitor therapy may have beneficial effects specific to the heart muscle of children with SV congenital heart disease.
• Treatment of primary cardiomyocytes with patient sera may represent a novel model for future studies of the mechanisms involved in SV heart failure.
in which primary cardiomyocytes are treated with SV heart disease patient sera±sildenafil to assess changes in pathological cardiac gene expression and the impact of PDE5i in vitro.
METHODS
The data, analytic methods, and study materials (with the exception of patient samples as these represent a limited resource) will be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Human Samples
All subjects gave informed consent and donated their hearts and blood to the institutional review board-approved Investigations of Pediatric Heart Disease tissue bank at the University of Colorado, Denver. Nonfailing RV tissues were from pediatric (<18 years of age) organ donors with normal heart structure and function, whose hearts could not be placed for technical reasons (size or blood type mismatch). Samples of nonfailing sera were obtained from control children with normal heart function. SV RV tissue and sera were from patients transplanted with SV of RV morphology who were transplanted secondary to systolic HF (SV heart disease of left ventricle or indeterminate morphology were excluded). Inclusion criteria for SV heart disease patients were as follows: age <18 years and abnormal SV systolic function on echocardiogram. Patients who were transplanted primarily for SV heart disease lacking these defined clinical characteristics were excluded. At the time of cardiac explant, the heart tissue was rapidly dissected in the operating room, flash frozen, and stored at −80°C until further use.
PDE Activity Assays
Approximately 150 mg of RV myocardium was homogenized and separated into nuclear, cytosolic, and sarcoplasmic reticulum-enriched microsomal fractions by differential centrifugation. cGMP hydrolytic activity in the cytosolic fraction was quantified at 30°C by the 2-step snake venom method with ( 3 H) cGMP (0.1 μmol/L) as substrate. 23, 24 Total cGMP hydrolytic activity was quantified by measuring activity without addition of PDE inhibitor. PDE5 activity was quantified by measuring activity in the absence and presence of 0.01 μmol/L sildenafil, a concentration that inhibits recombinant PDE5 submaximally (IC46) to minimize possible inhibition of other PDE families.
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PDE5-specific activity was calculated by dividing the difference in activity between the absence and presence of sildenafil by the fractional inhibition of PDE5 activity at this concentration. The amount of protein used per assay was adjusted to ensure that 20% (±15%) of the total cGMP was hydrolyzed during the assay.
Western Blots
Western blots were performed as described. 25 Protein was isolated from 10-to 25-mg frozen RV tissue in isoelectric focusing buffer at 4°C. PDE5A (Cell Signaling) and GAPDH (Santa Cruz Biotechnology) were quantified on the same blot. Blots were quantified using ImageJ (US National Institutes of Health).
Immunohistochemistry and Confocal Microscopy
Briefly, freshly procured RV tissue was fixed in 4% paraformaldehyde at 4°C for 4 to 12 hours, rinsed in PBS, and immersed in 30% sucrose solution for 6 to 12 hours at 4°C for cryoprotection. Fixed tissue was embedded and frozen in optical coherence tomography media, and tissue was cryosectioned at −18°C to −20°C into 6 to 10 µm sections and mounted on microscope slides. Slides were stored at −80°C for no longer than 1 month before processing. Sections were fixed in ice cold acetone for 10 minutes, rinsed in PBS, and blocked for 1 hour in blocking buffer (2% normal goat sera, 1% BSA, and 0.1% NP-40 in PBS). Primary antibodies rabbit PDE5A (1:100, Abcam) and mouse sarcomeric α actinin (1:400, Sigma Aldrich) were incubated overnight at 4°C, and Alexa Fluor-conjugated secondary antibodies (1:1000, Alexa 555 goat anti-mouse and Alexa 488 goat anti-rabbit, Sigma Aldrich) were incubated for 1 hour at room temperature. Nuclei were stained with 4',6-diamidino-2-phenylindole (1 µmol/L, Invitrogen) for 10 minutes at room temperature. Secondary antibody-only staining confirmed lack of nonspecific binding for all antibodies used. Slides were mounted in Prolong Diamond antifade mounting media (Thermo Fisher Scientific), and images were acquired on the Olympus FLUOVIEW FV1000 confocal laser scanning microscope at ×60 magnification (fluorescein isothiocyanate: 488 nm excitation, 520 nm emission; tetramethylrhodamine: 543 nm excitation, 618 nm emission; 4',6-diamidino-2-phenylindole: 405 nm excitation, 461 nm emission).
Cell Culture and Serum Treatment
Neonatal rat ventricular myocytes (NRVMs) were isolated from the ventricles of 1-to 2-day-old Sprague Dawley rats (Charles River) by enzymatic digestions as described. 26 NRVMs were treated with 2% human serum for 72 hours as described. 26 NRVMs were preincubated with 1.5 µmol/L sildenafil for 30 minutes before serum treatment. Efficiency of NRVM response was tested by treatment of cells with 10 −5 mol/L phenylephrine for 72 hours as a positive control. All animal protocols are in accordance with Public Health Service Animal Welfare Assurance, ID A3269-01, and approved by the University of Colorado, Denver-Animal Care and Use Committee.
RNA Isolation and RT-qPCR
NRVMs were homogenized in Qiazol (Qiagen), and RNA was extracted as per manufacturer's protocol. Human RV samples were homogenized in Qiazol, RNA was extracted using the RNeasy plus mini kit (Qiagen), and after extraction, RNA was treated with TURBO DNase (Thermo Fisher Scientific) as per manufacturer's protocol. cDNA was synthesized by using the Verso cDNA synthesis kit (Thermo Fisher Scientific) according to manufacturer's instructions. Gene expression was measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) as described, 27 with Power Sybr Green PCR Master Mix (Life Technologies). Expression levels of all transcripts were normalized to 18S rRNA, and all RT-qPCR data are represented on a Log 2 scale. RT-qPCR primers sequences are listed in Table II in the Data Supplement.
RNA Sequencing and Transcriptome Analysis
1X150 directional mRNA sequencing was performed on an Illumina hiSEQ 4000 (high-throughput mode), with an average of 38 to 44 million mapped reads per sample. Samples were demultiplexed and aligned to the reference genome Rattus norvegicus (Rnor_5.0) using gsnap. 28 High-throughput sequencing was used to produce gene counts for each of our 12 samples (n=3 nonfailing serum-treated NRVMs±PDE5i and n=3 SV heart disease serum-treated NRVMs±PDE5i, from 3 different NRVM preparations). 29 Counts of reads generated by high-throughput sequencing were normalized using edgeR. 30 Although RNA sequencing identified >20 000 genes, counts of ≥10 in any 1 sample were necessary for inclusion. After removal of low counts, 7690 genes remained. Significant changes in gene expression were calculated using an ANOVA and a post hoc Tukey with a nonstringent threshold of P<0.05. RNA sequencing on NRVMs was performed to generate hypotheses in regards to the human SV heart disease myocardium, and therefore there was no correction for multiplicity of measured values. Differentially expressed genes of interest were validated in a cohort of human samples. Hierarchical clustering and heatmap generation were performed using R (The R Foundation). Ingenuity Pathway Analysis (IPA) and Gene Ontology categorization using PANTHER were performed to investigate molecular pathways, biological processes, and toxicity functions associated with differentially regulated genes.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software), and statistical significance was set a priori at P<0.05. Normality of data was assessed, and nonnormally distributed groups were Log 2 transformed, after which all data were approximately normally distributed. Comparisons between 2 normally distributed groups were conducted using an unpaired t test. Comparisons of ≥3 normally distributed groups were conducted using a 1-way ANOVA; if the overall comparison reached significance, HolmSidak multiple comparisons post hoc tests were performed. Quantitative results in figures are shown as mean±SEM and in the text as mean±SD. For log-transformed data, the mean of the log-transformed data is reported.
RESULTS

Patient Characteristics
Aggregate characteristics for patients included in this study are listed in the Table. A more detailed description of individual subject characteristics is included in Table  I in the Data Supplement. The nonfailing tissue and blood group included 17 subjects with a median age of 8 years, an interquartile range of 3.1 to 13.6, and was 65% male. The SV heart disease tissue and blood group had 18 subjects with a median age of 2.6 years, an interquartile range of 0.9 to 4.8, and was 67% male. As expected, based on limited young donor availability, the SV heart disease group is significantly younger than the nonfailing group (P=0.004).
PDE5 Expression and Activity Are Increased in Human SV Heart Disease Myocardium
We quantified RV PDE enzymatic activity in the cytosolic fraction of 9 RV samples from patients with SV heart Aggregate characteristics for all patients included in this study. ACE indicates angiotensin-converting enzyme; n/a, not applicable; NRVM, neonatal rat ventricular myocytes; PDEi, phosphodiesterase inhibitor; RNAseq, RNA sequencing; RT-PCR, reverse transcription polymerase chain reaction; and SV, single ventricle.
*Non-PDEi inotrope includes dopamine, dobutamine, epinephrine, and norepinephrine.
disease and in 8 RV samples from normal nonfailing pediatric donor hearts ( Figure 1A and 1B). Although total RV cytosolic PDE activity was similar between SV heart disease and nonfailing groups (nonfailing=48.1±8.9; SV heart disease=48.8±15.2; P=0.73), PDE5-specific activity was significantly increased in the SV heart disease group, with the average PDE5-specific cGMP-hydrolyzing activity >3× higher in SV heart disease patients compared with nonfailing controls (nonfailing=4±3.1; SV=12.4±7.4; P=0.009). RV PDE5 protein expression was also quantified in 7 hearts from patients with SV heart disease and in 9 nonfailing pediatric donor hearts ( Figure 1C ). RV PDE5 expression was significantly increased in SV heart disease relative to nonfailing, with the mean signal intensity of PDE5 relative to the loading control GAPDH >8× higher in SV heart disease myocardium compared with nonfailing myocardium (nonfailing=−0.28±1.3; SV=2.8±1.2; P=0.0002). A subset of pediatric RV samples, 3 SV heart disease and 1 nonfailing RV, were subjected to histological staining for PDE5 localization ( Figure 2 ; Figure  I in the Data Supplement). We determined that PDE5 is expressed in pediatric RV myocardium and is localized primarily within cardiomyocytes as determined by colocalization with α-actinin in the z-disk region of the sarcomere.
SV Heart Disease Serum Induces Pathological Gene Expression Changes in Primary Cardiomyocytes
As an in vitro model of SV heart disease-related pathological cardiomyocyte remodeling, primary cardiomyocytes (NRVMs) were treated with serum from SV heart disease patients and serum from nonfailing controls (n=5 nonfailing; n=12 SV heart disease in a total of 7 NRVM preparations). The α-adrenergic receptor agonist phenylephrine was used as a positive control because it results in robust activation of the fetal gene program, a hallmark of pathological remodeling. 25 As compared with nonfailing serum treatment, SV heart disease serum treatment results in significant induction of prototypical pathological cardiac fetal genes brain natriuretic peptide and atrial natriuretic factor, as well as a significant reduction in the ratio of α-myosin heavy chain to β-myosin heavy chain in NRVMs (Figure 3 ).
PDE5 Inhibition Attenuates SV Heart Disease Serum-Induced Pathological Gene Expression Changes in Primary Cardiomyocytes
In addition, we used the SV heart disease serum-based in vitro model of cardiomyocyte remodeling to assess the intracellular consequences of PDE5 inhibition (n=4 nonfailing+PDE5i; n=9 SV heart disease+PDE5i in a total of 7 NRVM preparations). Although PDE5i had no significant effect on untreated NRVMs or those treated with nonfailing patient serum, PDE5i significantly attenuated SV heart disease serum-induced pathological cardiac gene expression changes (Figure 4) . Namely, brain natriuretic peptide and atrial natriuretic factor expression were significantly attenuated in the SV heart disease+PDE5i-treated group as expression levels were not significantly different from nonfailing+PDE5i controls and were significantly less than SV heart disease serum treatment alone. There was an increase in the ratio of α-myosin heavy chain to β-myosin heavy A, PDE5-specific enzymatic activity in nonfailing (NF) and SV heart disease. Bar equals mean±SEM, each point represents individual patient values, n=7 NF and n=13 SV RV samples; **Significant difference between groups, unpaired t test, P<0.05. B, Total PDE enzymatic activity in NF and SV heart disease. Bar equals mean±SEM, and each point represents individual patient values, n=7 NF and n=13 SV RV samples. C, Quantification of PDE5 protein relative to GAPDH protein in NF and SV heart disease. Quantitative data were log 2 transformed, bar equals log 2 (mean±SEM), each point represents individual patient values, n=9 NF and n=8 SV RV samples; ***Significant difference between groups, unpaired t test, P<0.001. A representative blot of PDE5 and GAPDH protein in NF and SV RV is shown on the right. chain in the SV heart disease+PDE5i group, such that expression levels were not significantly different from nonfailing+PDE5i controls.
Transcriptome Profiling Indicates SV Heart Disease Serum Induces Significant Transcriptional Changes and Dysregulated Cardiotoxicity Pathways in Primary Cardiomyocytes, That Are Normalized by PDE5i
Next-generation sequencing (RNA sequencing) on a subset of serum-treated NRVMs±the PDE5i sildenafil (n=3 nonfailing serum-treated NRVMs±PDE5i and n=3 SV heart disease serum-treated NRVMs±PDE5i, from 3 different NRVM preparations) identified >20 000 genes. Genes with counts <10 were removed, and further analysis was performed using the resulting 7690 genes. Of these, 1135 were significantly differentially expressed between nonfailing and SV heart disease serum-treated groups (P<0.05; Figure 5A and 5B). Of the 1135 differentially expressed genes, 607 genes were significantly upregulated, and 528 genes were significantly downregulated ( Figure 5A ). Unsupervised hierarchical clustering separated nonfailing and SV heart disease serum-treated cells ( Figure 5B) . A list of all 1135 differentially expressed genes is given in Table III in the Data Supplement.
Pathway analysis performed using Qiagen IPA software revealed multiple dysregulated canonical pathways associated with SV heart disease serum treatment ( Figure 5C ). Most prominently, signaling pathways involved in axonal guidance, ceramide, peroxisome proliferator-activated receptor, p38 mitogen-activated protein kinase (MAPK), phospholipase C (PLC), cardiac hypertrophy, aryl hydrocarbon receptor, B cell receptor, actin cytoskeleton, and ephrin A signaling were sig- Sectioned SV heart disease tissue was stained with fluorescently labeled secondary antibodies to primary sarcomeric α actinin (red), primary PDE5 (green) and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). The merged confocal laser microscopy images demonstrate that PDE5 is expressed in SV heart disease cardiomyocytes. All images are at ×60 magnification, scale bar, 20 µmol/L.
Figure 3. Single ventricle (SV) heart disease serum induces pathological gene expression changes in cardiomyocytes in vitro.
A, Neonatal rat ventricular myocytes (NRVMs) were treated with either phenylephrine (PE) or with sera from nonfailing (NF) or SV heart disease patients for 72 h. RNA was harvested for quantitative reverse transcription polymerase chain reaction (RT-PCR). B, Log 2 relative mRNA expression of prototypical pathological cardiac genes (brain natriuretic peptide [BNP] , atrial natriuretic factor [ANF], β myosin heavy chain [MHC] , and αMHC) in NRVMs. For all groups, bar equals log 2 (mean±SEM), *significant difference between groups, 1-way ANOVA, Holm-Sidak multiple comparisons (**P<0.01, ***P<0.001, ****P<0.0001), n=5 NF, n=16 SV heart disease, n=10 PE treatments in a total of 7 NRVM preparations.
nificantly enriched (P<0.01) in SV heart disease serumtreated NRVMs relative to nonfailing serum-treated NRVMs. In addition to cardiac hypertrophy signaling, a more detailed IPA analysis of cardiac-specific pathways revealed multiple dysregulated cardiotoxicity functions, including significant differential expression (P<0.05) of pathways related to cardiac dysfunction, arteriopathy, cardiac damage, cardiac fibrosis, infarction, HF, congenital heart anomalies, cardiac cell death, and arrhythmias ( Figure 5D ).
PANTHER was used to further categorize the 1135 differentially expressed transcripts based on implicated biological processes. The top 3 categorizations indicate that a majority of the differentially expressed genes are involved in cellular processes (28%; eg, cell communication, cell cycle, and movement of cellular components), metabolic processes (23%; eg, primary metabolism and nitrogen compound metabolism), and response to stimuli (9%; eg, stress response and immune response; Figure 5E ).
In addition, more than half of the 1135 differentially expressed transcripts were normalized (P>0.05) by PDE5i, and unsupervised hierarchical clustering separated SV heart disease and SV heart disease+PDE5i serumtreated cells ( Figure 6A ). Namely, 335 (55%) of the 607 significantly upregulated genes in the SV heart disease serum-treated group were no longer significantly different in the SV heart disease+PDE5i group relative to nonfailing+PDE5i ( Figure 6B ) while 314 (60%) of the 528 significantly downregulated genes in the SV heart disease group were no longer significantly different in the SV heart disease+PDE5i group relative to nonfailing+PDE5i ( Figure 6C ). IPA analysis of all 649 genes that were normalized with PDE5i in SV heart disease serum-treated NRVMs predicted normalization of many differentially activated signaling pathways, including normalization of ceramide, p38 MAPK, PLC, cardiac hypertrophy, actin cytoskeleton, and oxidative stress response signaling ( Figure 6D ). IPA analysis also predicted normalization of SV heart disease seruminduced cardiotoxicity pathways, including normalization of cardiac and ventricular hypertrophy signaling, as well as normalization of genes involved in cardiac dysfunction ( Figure 7A-7C) . A list of all 649 genes that were normalized by PDE5i are included in Table IV in the Data Supplement.
Representative genes from the top 6 most significantly differentially regulated signaling pathways activated by SV heart disease serum treatment, including ceramide, p38 MAPK, PLC, cardiac hypertrophy, actin cytoskeleton, and oxidative stress response signaling ( Figure II in the Data Supplement), were chosen for further analysis. Confirmatory analysis by RT-qPCR was performed on human RV tissue for representative genes in each pathway, including (1) ceramide kinase, 31 (2) cAMP-responsive transcription factor 5, 32,33 (3) nonreceptor tyrosine kinase FYN, 34, 35 (4) cardiac ankyrin repeat domain ANKRD1, 36 ,37 (5) α-actinin isoform ACTN2, 38, 39 and (6) musculoaponeurotic fibrosarcoma transcription factor K. 40 RT-qPCR revealed that these representative in NRVMs. For all groups, bar equals log 2 (mean±SEM), *significant difference between groups, 1-way ANOVA, Holm-Sidak multiple comparisons (*P<0.05, ***P<0.001, ****P<0.0001), n=5 NF, n=16 SV heart disease, n=4 NF+PDE5i, n=14 SV heart disease+PDE5i in a total of 7 NRVM preparations.
Figure 5. Single ventricle (SV) serum induces significant transcriptional changes and dysregulated cardiotoxicity pathways in vitro.
A, Volcano plot representation of all the 20 398 transcripts detected by RNA sequencing depicted as the log 2 fold-changes in expression (x axis) and the log odds of a gene being differentially expressed (y axis), highlighting the 1135 transcripts that are significantly differentially expressed between nonfailing (NF) vs single ventricle (SV) heart disease serum-treated neonatal rat ventricular myocytes (NRVMs; above dotted line). ANOVA, −log 10 (P value) >1.3 or P<0.05. B, Heat map of the 1135 significantly differentially expressed transcripts (raw fragments per kilobase of transcript per million mapped reads, FPKM values). Unsupervised hierarchical clustering separated NF (n=3) and SV heart disease (n=3) serum-treated NRVM samples. C, Significantly dysregulated canonical pathways in NF vs SV heart disease serum-treated NRVMs identified with Ingenuity Pathway Analysis (IPA) using the 1135 transcripts that changed significantly in all 3 SV heart disease-treated cell groups. Fisher exact test, −log 10 (P value) >2.9 or P<0.001. D, Significantly dysregulated cardiotoxicity functions in NF vs SV heart disease serum-treated NRVMs identified with IPA using the 1135 transcripts that changed significantly in all 3 SV heart disease serum-treated cell groups. Fisher exact test, −log 10 (P value) >1.3 or P<0.05. E, Categorization of Gene Ontology (GO) annotations for biological processes in NF vs SV heart disease serum-treated NRVMs identified with PANTHER using the 1135 transcripts that changed significantly in all 3 SV heart disease-treated cell groups. MAPK indicates mitogen-activated protein kinase; NO, nitric oxide; PPAR, peroxisome proliferator-activated receptor; and ROS, reactive oxygen species. A, Heat map summary of the 649 significantly differentially expressed transcripts that were normalized by PDE5i (average fold change relative to nonfailing [NF], n=3 NF, n=3 NF+PDE5i, n=3 SV heart disease, n=3 SV heart disease+PDE5i in a total of 3 neonatal rat ventricular myocytes [NRVM] preparations). Unsupervised hierarchical clustering separated NF, NF+PDE5i, SV heart disease, and SV heart disease+PDE5i serum-treated samples. B, SV heart disease serum-induced upregulated gene expression changes were compared with gene expression changes that were not significantly different between NF+PDE5i and SV heart disease+PDE5i serum-treated groups. The Venn diagram indicates significantly upregulated genes that were normalized with PDE5i. C, SV heart disease serum-induced downregulated gene expression changes were compared with gene expression changes that were not significantly different between NF+PDE5i and SV heart disease+PDE5i serum-treated groups. The Venn diagram indicates significantly downregulated genes that were normalized with PDE5i. D, Activation z scores of significantly dysregulated canonical pathways in NF vs SV heart disease serum-treated NRVMs compared with NF+PDE5i vs SV heart disease+PDE5i serum-treated NRVMs. MAPK indicates mitogen-activated protein kinase; and PPAR, peroxisome proliferator-activated receptor.
genes were significantly upregulated in SV RV relative to nonfailing control RV, consistent with the SV heart disease sera NRVM treatment findings (Figure 8 ).
DISCUSSION
Long-term survival and quality of life in SV heart disease patients ultimately depend on preservation of RV function, particularly as more children with complex congenital heart defects are surviving into adulthood. 41 There are no proven therapies to treat or prevent RV failure in SV heart disease, and persistence of RV dysfunction may reflect irreversible adverse remodeling that is presumably a precursor to eventual HF. 42 There remains a critical need to better understand the mechanisms of SV heart disease failure and to identify clinically relevant pathways, biomarkers of disease progression, and therapeutic targets. In this study, we demonstrate that myocardial PDE5 expression and activity are significantly elevated in SV heart disease patients relative to nonfailing controls and that PDE5 is expressed in SV heart disease cardiac myocytes. Moreover, in vitro treatment of primary cardiomyocytes with SV heart disease patient sera induces gene expression changes indicative of pathological myocardial remodeling, cardiac hypertrophy, and cardiac dysfunction, which are abrogated by PDE5i. Finally, confirmatory analysis in human RV tissue revealed that gene expression changes induced by A, Activation z scores of significantly dysregulated cardiotoxicity pathways in nonfailing (NF) vs SV heart disease serum-treated neonatal rat ventricular myocytes (NRVMs) compared with NF+PDE5i vs SV heart disease+PDE5i serum-treated NRVMs. B, Heat map summary of the genes predicted to be involved in cardiac hypertrophy signaling based on Ingenuity Pathway Analysis (IPA) that were normalized by PDE5i (average fold change relative to NF, n=3 NF, n=3 NF+PDE5i, n=3 SV heart disease, n=3 SV heart disease+PDE5i in a total of 3 NRVM preparations). C, Heat map summary of the genes predicted to be involved in cardiac dysfunction signaling based on IPA, which were normalized by PDE5i (average fold change relative to NF, n=3 NF, n=3 NF+PDE5i, n=3 SV heart disease, n=3 SV heart disease +PDE5i in a total of 3 NRVM preparations). SV heart disease serum in primary cardiomyocytes are similar to those seen in SV heart disease myocardium. Together, these data provide an important foundation for future mechanistic studies on PDE5i in SV heart disease and highlight a novel SV heart disease serumbased model that can be used to identify potential drug targets relevant to myocardial remodeling in the pediatric SV heart disease population.
PDE5 Upregulation in SV Heart Disease
There is mounting preclinical and clinical evidence on the potentially beneficial cardiac effects of PDE5i; however, their use in children with heart disease remains primarily focused on modulating pulmonary blood flow. Although PDE5i therapy in failing SV heart disease patients has been associated with improved hemodynamics, exercise tolerance, and cardiac function, 10, 12, 43 the direct effects of PDE5i on the SV heart disease myocardium are unknown. Given the significant increase of PDE5 mRNA, 20 protein, and activity in SV heart disease RV and the presence of PDE5 in SV heart disease cardiomyocytes, these findings suggest that in addition to effects on the pulmonary vasculature, PDE5i may directly target the myocardium. The specific mechanisms by which PDE5i may augment cardiac function remain to be determined.
PDE5-Mediated Cardiomyocyte Remodeling
We and others have previously reported that circulating factors present in patient serum or plasma can be important paracrine modulators of cardiac gene expression. 26, 44 Here, we show that treatment of primary cardiomyocytes with SV heart disease patient serum induces changes in gene expression with similar directionality as in SV hearts 27 and a pediatric rodent model of RV hypertrophy. 45 Paracrine effects on cardiac remodeling can be mediated by a myriad of factors present in the circulation, and the specific factors modulating SV heart disease serum-induced cardiomyocyte remodeling remain to be determined.
Transcriptome analysis of SV heart disease serumtreated primary cardiomyocytes suggests dysregulation of genes involved in various cellular and metabolic processes, including a high number of genes involved in cardiac remodeling, hypertrophy, and dysfunction. Pathway analysis of differentially expressed genes in SV heart disease serum-treated cardiomyocytes also suggests enrichment of several other pathways, including significant activation of ceramide, p38 MAPK, PLC, actin cytoskeleton, and oxidative stress response signaling.
Many of these dysregulated canonical pathways have known roles in cardiac hypertrophy and dysfunction. For example, ceramide signaling has been implicated in a variety of physiological functions, 31 and a specific species of ceramide has been shown to promote cardiomyocyte hypertrophy through generation of reactive oxygen species 46 while inhibition of ceramide signaling using a sphingosine kinase-1 inhibitor in a mouse model of hypoxia-induced pulmonary arterial hypertension resulted in reduced RV hypertrophy and cardiomyocyte death, without affecting vascular remodeling. 47 In addition, PLC enzymes are important for intracellular signaling and can be activated by nonreceptor tyrosine kinases, such as FYN. 34, 35 It has been shown that cardiomyocyte hypertrophy and cardiac dysfunction can occur via stimulation of PLC, resulting in generation of potent phospholipid-derived second messenger lipid molecules that can alter cardiomyocyte signaling. 48, 49 Moreover, the p38 MAPK signaling pathway is known as one of the key sensors of cellular stress, and signal transduction occurs via a cascade culminating in activation of key transcription factors, including those in the cAMP-responsive element binding family (eg, cAMP-responsive element binding protein 5).
33 p38 MAPK signaling has a variety of roles in the cardiovascular system, including regulation of cardiomyocyte proliferation, apoptosis, and hypertrophy. 32, 50, 51 In addition, structural cytoskeletal alterations (eg, alterations in anchor proteins, such as α-actinins), 52 both within cardiac myocytes and of the extracellular matrix, contribute to ventricular remodeling and cardiac dysfunction. 38, 52, 53 Finally, under pathological conditions, oxidative stress in cardiomyocytes is considered a major stimulant of signal transduction and can induce inflammatory cytokines and MAPKs (eg, musculoaponeurotic fibrosarcoma transcription factor K). 40, 54 Our transcriptome analysis of serum-treated primary cardiomyocytes revealed that more than half of the differentially expressed transcripts between SV heart disease serum-treated NRVMs and nonfailing serumtreated NRVMs were normalized by PDE5i, including normalization of ceramide, p38 MAPK, PLC, actin cytoskeleton, and oxidative stress signaling, as well as normalization of SV heart disease serum-induced cardiotoxicity pathways, such as cardiac hypertrophy and dysfunction. Thus, these pathways may serve as potential therapeutic targets in this population and warrant future study. In summary, the in vitro model used in this study recapitulates some relevant SV myocardial gene expression patterns, poses no risk to children, and provides a useful mechanistic platform to investigate PDE5, as well as other signaling pathways altered by SV heart disease physiology. Figure 8 Continued. NF+phosphodiesterase-5 inhibitor (PDE5i), n=3 SV heart disease, n=3 SV heart disease+PDE5i in a total of 3 NRVM preparations. For all human RV tissue groups, data are depicted as log 2 relative mRNA expression, bar equals log 2 (mean±SEM); asterisks denote significant difference between groups, unpaired t test (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001), n=7 NF, n=14 SV heart disease.
Limitations
There are important limitations of this study. The tissue bank-based aspect of this study is inherently cross-sectional, and as such, proof of mechanistic associations or knowing whether changes are pathological or compensatory is not possible. Because of the relative rarity of SV heart disease, it is not possible for us to determine the influence of age, prior surgical procedures, or the temporal relationship of expression/activity changes in our findings. Secondary to the current widespread use of PDE inhibitors in the SV heart disease population, it is not possible to exclude all patients on a PDE5i or to determine whether PDE5 upregulation is secondary to PDE3i (millrinone) treatment. It is important to note, however, that there was no significant difference in PDE5 activity or expression between SV heart disease patients based on treatment with the PDE5i sildenafil. Because our experiments were performed using explanted RV myocardium, we acknowledge that the data are not necessarily representative of cardiomyocytes alone, and contributions of the extracellular matrix, fibroblasts, and endothelial cells are unknown. Finally, we acknowledge that the unadjusted P value (P<0.05) used in our primary cardiomyocyte RNA sequencing data analysis may result in false positives. However, our goal was to identify a larger gene set to generate hypotheses on gene expression changes relevant in the human SV heart disease myocardium.
Conclusions
Findings from this study suggest that elevated PDE5 in failing SV heart disease myocardium may contribute to adverse myocardial remodeling, and in addition to effects on the pulmonary vasculature, PDE5i may provide direct myocardial benefit in this population. These results underscore the importance of pediatric-specific investigations and justify attempts to improve the understanding of SV heart disease-specific molecular mechanisms leading to HF.
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